Patents Examined by Taeyoon Kim
  • Patent number: 11446342
    Abstract: The present disclosure relates to the field of microbial technology, and discloses a composite probiotics and the use thereof. The composite probiotics in the present disclosure is consisted of Bifidobacterium adolescentis CCFM8630, Lactobacillus reuteri CCFM8631, Lactobacillus rhamnosus CCFM1044 and Lactobacillus casei CCFM711, whose effect of alleviating metabolic syndrome is significantly better than that of CCFM8630 or CCFM8631 alone or combination of the two, especially in aspects of lowering contents of serum low density lipoprotein, total cholesterol, and liver triglyceride and contents of serum alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and IFN-?, and increasing contents of liver glutathione and superoxide dismutase, etc. The extent of decrease or increase is increased by 7.91% to 837.31% compared with the formulations of CCFM8630 or CCFM8631 alone or combination of the two probiotics. The combination of the four probiotics can achieve a significant synergistic effect.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: September 20, 2022
    Assignee: INFINITUS (CHINA) COMPANY LTD.
    Inventors: Fangli Ma, Wei Chen, Gang Wang, Xiaofeng Zhu, Yuanyuan Wang, Junyong Xiao, Hao Zhang, Jianxin Zhao
  • Patent number: 11447749
    Abstract: The application discloses a method for obtaining MSC-derived cells with improved transplantation properties from MSC, the method comprising a cell size reduction step, wherein said cell size reduction step is characterized by contacting MSC or MSC-derived cells in vitro or ex vivo with heparin or a derivative or analogue thereof at a concentration of at least 0.01 IU/ml. The application further provides a method for obtaining mesenchymal stem cell-derived cells from mesenchymal stem cells (MSC) comprising contacting MSC in vitro or ex vivo with FGF-2, TGF? and at least 0.01 IU/ml heparin or a derivative or analogue thereof. The invention also provides the so-obtained cells and cell populations, as well as further products comprising such and uses thereof.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: September 20, 2022
    Assignee: Bone Therapeutics S.A.
    Inventors: Sandra Pietri, Xuan Mai Nguyen, Enrico Bastianelli, Sabrina Ena, Pierre-Yves Laruelle, Isabelle Tytgat
  • Patent number: 11439731
    Abstract: The invention relates to the technical filed of tissue engineering and 3D printing, particularly relates to an artificial tissue progenitor and a method for preparing the same.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: September 13, 2022
    Assignee: REVOTEK CO., LTD.
    Inventors: Yujian James Kang, Xiao Zuo, Mingchun Du
  • Patent number: 11419962
    Abstract: A method of making a spheroid is provided that includes the step of providing a suspension having one or more biologically-relevant materials dispersed within a biocompatible medium. An amount of a hydrophilic material is deposited on a defined area of a super-hydrophobic surface, and a droplet of the suspension is bioprinted onto the hydrophilic material positioned on the super-hydrophobic to thereby create the spheroid.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: August 23, 2022
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Stuart K. Williams, Brian C. Gettler, Joseph S. Zakhari, Piyani S. Gandhi
  • Patent number: 11415574
    Abstract: This invention provides methods for diagnosing Alzheimer's disease in a symptomatic human subject, and for determining whether a human subject is predisposed to becoming afflicted with Alzheimer's disease. These methods employ the steps of (a) culturing a subject's lymphocytes with a suitable basement membrane matrix to permit the lymphocytes to aggregate; (b) measuring the resulting lymphocyte aggregation; and (c) based on such measurement, either diagnosing Alzheimer's disease or determining a predisposition to it, as appropriate.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: August 16, 2022
    Assignee: NeuroDiagnostics LLC
    Inventors: Florin Valentin Chirila, Daniel L. Alkon
  • Patent number: 11413313
    Abstract: Disclosed is a composition for prevention, treatment or ameliorating of atopic dermatitis, the composition containing a monoclonal stem cell obtained via improved subfractionation culturing of a stem cell, a preparation method thereof, and a method for treating atopic dermatitis using the same. According to the improved subfractionation culturing and proliferation method of the stem cell, a desired amount of the monoclonal stem cells may be obtained in a massive manner in a short time via the rapid proliferation of the monoclonal stem cell. The monoclonal mesenchymal stem cell as obtained has an enhanced effect of treatment, prevention or ameliorating of atopic dermatitis, and thus may be usefully used for an atopic dermatitis treatment agent.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: August 16, 2022
    Assignee: SCM LIFESCIENCE CO., LTD.
    Inventors: Sun Uk Song, Si Na Kim, Jeong Hyun Moon
  • Patent number: 11413311
    Abstract: Methods of treating multiple sclerosis are provided, comprising parenterally administering glatiramer acetate in a sustained-release depot form, and administering adipose-derived stem cells into the central nervous system. According to some aspects the combined treatments provide synergistic effects. In particular the combined therapies offer benefits to progressive forms of multiple sclerosis.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: August 16, 2022
    Assignees: MAPI PHARMA LTD., STEM CELL MEDICINE LTD.
    Inventors: Ehud Marom, Nadav Bleich Kimelman, Frida Grynspan
  • Patent number: 11406736
    Abstract: Provided herein are methods of making an ECM gel from vascular tissue. Also provided herein are ECM compositions prepared from vascular tissue, and methods of use of those compositions, for example in treatment of aneurysms, and for vascularization or re-vascularization.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: August 9, 2022
    Assignee: University of Pittsburgh—Of the Commonwealth Systems of Higher Education
    Inventors: Stephen F. Badylak, George R. Fercana, Jr., Thomas G. Gleason, Julie Anne Phillippi
  • Patent number: 11401508
    Abstract: The present invention provides methods for isolating human cardiac ventricular progenitor cells (HVPs), wherein cultures of day 5-7 cardiac progenitor cells are negatively selected for one or more first markers expressed on human pluripotent stem cells, such as TRA-1-60, to thereby isolate HVPs. The methods can further include positive selection for expression of a second marker selected from the group consisting of JAG1, FZD4, LIFR, FGFR3 and TNFSF9. Large populations, including clonal populations, of isolated HVPs that are first marker negative/second marker positive are also provided. Methods of in vivo use of the HVPs for cardiac repair or to improve cardiac function are also provided. Methods of using the HVPs for cardiac toxicity screening of test compounds are also provided.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: August 2, 2022
    Assignee: Procella Therapeutics AB
    Inventors: Kenneth R. Chien, Jonathan Clarke, Miia Lehtinen, Kylie Foo, Chuen Yan Leung
  • Patent number: 11401510
    Abstract: Described herein is a method of generating in-vitro differentiated airway basal cells and compositions thereof. Also described herein is a method of treating a pulmonary disease comprising administering the in-vitro differentiated airway basal cells and compositions thereof. In another aspect, described herein is a disease model comprising patient-derived or genetically modified in-vitro differentiated airway basal cells and compositions thereof.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: August 2, 2022
    Assignees: TRUSTEES OF BOSTON UNIVERSITY, THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Finn Joseph Hawkins, Darrell N. Kotton, Shingo Suzuki, Brian R. Davis, Cristina BarillĂ 
  • Patent number: 11395863
    Abstract: A method is disclosed for modifying a sheet-shaped cell culture containing at least two types of cells. The method includes soaking the sheet-shaped cell culture in a low nutrient isotonic solution; and changing a content ratio of the at least two cell types constituting the sheet-shaped cell culture.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: July 26, 2022
    Assignee: TERUMO KABUSHIKI KAISHA
    Inventors: Kenji Oyama, Ryohei Takeuchi, Toshikazu Takeuchi
  • Patent number: 11376287
    Abstract: Provided is an agent having an action on a transcellular ion transporter in the intestinal tract, the agent containing a bacterium of the genus Bifidobacterium or the genus Lactobacillus, or a treated product thereof, with the proviso that the case where the ion transporter is a chloride channel and the action is inhibition; the case where the ion transporter is Na+K+Cl? cotransporter (NKCC1) and the action is inhibition; the case where the bacterium is Bifidobacterium infantis 35624; and the case where the bacterium is Lactobacillus salivarius UCC118 are excluded. The agent of the present invention is useful in activation of chloride channels, prevention or treatment of renal diseases, and/or promotion of defecation, and therefore, usable as a medicament, a supplement, etc.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: July 5, 2022
    Assignee: Biofermin Pharmaceutical Co., Ltd.
    Inventors: Ayako Maeda, Masaki Shimakawa, Hiroshi Ohno
  • Patent number: 11371020
    Abstract: This disclosure relates to methods of generating pacemaker cells for use in therapeutic strategies that address a heart that beats abnormally. In certain embodiments, one mixes cells with an epithelial-to-mesenchymal transformation inhibitor in combination with a nucleic acid encoding a transcription factor such as a vector that encodes a transcription factor such as Tbx18 in operable combination with a eukaryotic promoter to produce pacemaker cells that are then transplanted into the heart.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: June 28, 2022
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventor: Hee Cheol Cho
  • Patent number: 11366115
    Abstract: Provided herein are methods and compositions relating, in part, to the generation and isolation of human lung progenitor cells from pluripotent stem cells.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: June 21, 2022
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Darrell N. Kotton, Finn Hawkins
  • Patent number: 11365396
    Abstract: Provided are an in vitro fibrosis model, a method of preparing the in vitro model, and use of the in vitro model, the in vitro model including a cell cluster differentiated from mesenchymal cells, wherein the cell cluster exhibits pathological characteristics of fibrosis.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: June 21, 2022
    Assignee: S-BIOMEDICS
    Inventors: Sang Heon Kim, Kwi Deok Park, Kang Won Lee, Thanavel Rajangam
  • Patent number: 11359178
    Abstract: The present invention provides a method for producing parasympathetic neurons from neural crest cells or autonomic neural progenitor cells derived therefrom, comprising a step of culturing the neural crest cells or autonomic neural progenitor cells derived therefrom in the presence of a cAMP production promoter, a BDNF signaling pathway activator, a GDNF signaling pathway activator, an NGF signaling pathway activator, an NT-3 signaling pathway activator, vitamin C, a protein kinase C activator, and a retinoic acid receptor agonist.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: June 14, 2022
    Assignee: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Yuzo Takayama, Yasuyuki Kida
  • Patent number: 11344582
    Abstract: The disclosure relates to oligodendrocyte-biased glial progenitor cells and methods of making, isolating, and using such cells.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: May 31, 2022
    Assignee: UNIVERSITY OF ROCHESTER
    Inventors: Steven Goldman, Fraser J. Sim
  • Patent number: 11312941
    Abstract: The disclosure provides stem cells which express high levels of Angeopoetin-1 (Ang1) and methods for their production. Such stem cells may be used in a range of therapeutic applications.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: April 26, 2022
    Assignee: MESOBLAST INTERNATIONAL SARL
    Inventors: Silviu Itescu, Paul Simmons
  • Patent number: 11311017
    Abstract: Storage-stable compositions for generating antimicrobial activity are described. The compositions comprise an enzyme that is able to convert a substrate to release hydrogen peroxide, and an unrefined natural substance, such as a honey, that includes a substrate for the enzyme. In certain embodiments, the enzyme is a purified enzyme. In other embodiments, the substrate lacks catalase activity, and the enzyme is additional to any enzyme activity able to convert the substrate to release hydrogen peroxide that may be present in the unrefined natural substance. The storage-stable compositions do not include sufficient free water to allow the enzyme to convert the substrate. Use of the compositions to treat microbial infections and wounds is described, as well as methods for their production.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: April 26, 2022
    Assignee: MATOKE HOLDINGS LIMITED
    Inventors: Thomas Patton, James Brennan, John Reginald Barrett, Ian Staples
  • Patent number: 11297831
    Abstract: Technologies for cryopreserving ungulate embryos for implantation into recipient females are described.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: April 12, 2022
    Assignee: ABS Global, Inc.
    Inventor: Bruno Valente Sanches